Perspective Therapeutics (CATX) Net Cash Flow (2010 - 2026)

Perspective Therapeutics has disclosed Net Cash Flow across 17 years of filings, most recently posting $23.3 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $23.3 million, up 235.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.6 million (up 109.77% YoY), and the FY2025 annual result was -$31.0 million, down 159.34% from the prior year.
• Net Cash Flow came in at $23.3 million for Q1 2026 at Perspective Therapeutics, up from $3.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $132.9 million in Q1 2024 to a low of -$164.9 million in Q4 2024.
• The 5-year median for Net Cash Flow is -$8.1 million (2023), against an average of -$2.6 million.
• Peak annual rise in Net Cash Flow reached 1451.13% in 2024, while the deepest fall reached 1785.23% in 2024.
• Perspective Therapeutics' Net Cash Flow stood at -$34.9 million in 2022, then soared by 74.94% to -$8.7 million in 2023, then plunged by 1785.23% to -$164.9 million in 2024, then soared by 102.35% to $3.9 million in 2025, then jumped by 503.65% to $23.3 million in 2026.
• The last three Net Cash Flow figures came in at $23.3 million (Q1 2026), $3.9 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.